spacer
home > white papers > Assessing the Integrity of Pharmaceutical Packaging Using the Sepha Blisterscan and Conventional Blue Dye Leak Testing Methods - Sepha Limited
WHITE PAPERS
logo_Sepha_Limi4.jpg

Sepha Limited

phone +44 (0)2890 484848
email info@sepha.com
web http://www.sepha.com
email Unit 25 Carrowreagh Business Park, Carrowreagh Road, Dundonald, Belfast BT16 1QQ

Assessing the Integrity of Pharmaceutical Packaging Using the Sepha Blisterscan and Conventional Blue Dye Leak Testing Methods

A new whitepaper by a leading packaging expert from the University of Ulster, Dr Dorian Dixon, into the integrity of pharmaceutical packaging has established that existing methods for testing the seal integrity of blister packs are not as accurate as newer, technology based test equipment.
Assessing the Integrity of Pharmaceutical Packaging Using the Sepha Blisterscan and Conventional Blue Dye Leak Testing Methods
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Pharmaceutical and Medical Industry Increasingly Demands Automated Testing Solutions

After the manufacturing processes in pharmaceutical and medical industries reached a high level of automation in recent years, manufacturers are more committed to automating their testing processes as well. Production-related tests as well as tests for product release are to be largely automated. In addition to higher specimen throughput, an increase in reproducibility through the elimination of operator influence is a main objective for manufacturers. Zwick Roell offers various levels of automation for testing syringes, insulin pens, and auto injectors.
More info >>


White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>


Industry Events

Clinical Trial Supply Southeast 2018

2-3 October 2018, Cary, North Carolina

Clinical Trial Supply Southeast will return to Cary, North Carolina for fall 2018. Part of our global series of events, this show will attract the leading biotech and pharma companies from the Southeast region, the event will focus on how companies can adapt their supply chains to fit into the highly regulated world.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement